Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.36 |
| ▸ | GCGR | P47871 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.32 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17247965 | 0.88 | SLC2A1 (0.40) | SLC2A1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL112039 | 0.87 | SLC2A1 (0.41) | SLC2A1ALDH1A1MAPTSMN1; SMN2LMNA | |
| Cyclohexanone SCHEMBL3913013 | 0.80 | ALDH1A1 (0.42) | SLC2A1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL11210823 | 0.79 | SLC2A1 (0.34) | SLC2A1 | |
| SCHEMBL4868148 | 0.78 | HPGD (0.40) | ALDH1A1MAPTSMN1; SMN2LMNAGAA | |
| SCHEMBL401756 | 0.78 | HPGD (0.40) | ALDH1A1MAPTSMN1; SMN2LMNAGAA | |
| SCHEMBL9912797 | 0.76 | ALDH1A1 (0.31) | SLC2A1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL11450694 | 0.74 | SLC2A1 (0.32) | SLC2A1 | |
| SCHEMBL5918114 | 0.74 | SLC2A1 (0.32) | SLC2A1 | |
| SCHEMBL10427966 | 0.73 | SLC2A1 (0.39) | SLC2A1ALDH1A1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304762-B2 | Tetrathiafulvalene derivatives and organic thin-film transistor | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304762-B2 | Tetrathiafulvalene derivatives and organic thin-film transistor | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100213444-A1 | ORGANIC SEMICONDUCTOR AND ORGANIC THIN-FILM TRANSISTOR | AUGME TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100213444-A1 | ORGANIC SEMICONDUCTOR AND ORGANIC THIN-FILM TRANSISTOR | AUGME TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-7414040-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060035958-A1 | Method of treating diabetes and related conditions | MERCK & CO., INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050234020-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1556059-A1 | THROMBOPOIETIN MIMETICS | Smithkline Beecham (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1538903-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024066-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003103686-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-0093853-A1 | Substituted derivatives of 3-isopropyl cyclopentanone, their preparation and use as perfumes and compositions containing these derivatives | HÜLS AKTIENGESELLSCHAFT (DE) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100213444-A1 | ORGANIC SEMICONDUCTOR AND ORGANIC THIN-FILM TRANSISTOR | OR10J3, TMEM109, TMT1A | SLC2A1 1198/4885ALDH1A1 2085/4885MAPT 1283/4885 |
| US-20050234020-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | SLC2A1 4438/4885ALDH1A1 1012/4885MAPT 4627/4885 |
| US-20060035958-A1 | Method of treating diabetes and related conditions | GLP1R, GPR119, GCGR | SLC2A1 26/4885ALDH1A1 2972/4885MAPT 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.